Werewolf Therapeutics (HOWL) Income Statement: Revenue & Earnings

Werewolf Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Werewolf Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	1.89	1.56	16.40	0.00	0.00
Cost of Revenue	53.09	38.91	50.96	33.98	0.00
Gross Profit	-51.20	1.56	-34.56	-33.98	0.00
Operating Expenses
Research & Development	56.43	41.78	53.76	35.27	16.64
Selling, General & Administrative	22.39	18.67	21.50	14.82	5.76
Operating Expenses	22.39	60.45	21.50	50.09	22.40
Operating Income	-73.59	-40.50	-56.06	-50.09	-22.40
Other Income/Expense
Interest Income	6.67	7.42	1.91	0.10	0.06
Interest Expense	-4.66	-3.14	0.00	0.00	0.00
Other Income/Expense	1.62	-18.76	0.34	-0.10	7.30
Income
Income Before Tax	-70.52	-34.27	-53.81	-49.98	-15.04
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-70.52	-37.37	-53.81	-49.98	-15.04
Net Income - Continuous Operations	-70.52	-37.37	-53.81	-49.98	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-71.78	-33.97	-54.95	-49.25	-22.25
EBIT	-73.59	-37.37	-56.06	-49.98	-22.40
Depreciation & Amortization	1.81	1.76	1.10	0.20	0.15
Earnings Per Share
Basic EPS	-2.00	-1.00	-2.00	-11.00	-28.00
Diluted EPS	-2.00	-1.00	-2.00	-11.00	-28.00
Basic Shares Outstanding	43.33	35.65	28.86	18.46	1.01
Diluted Shares Outstanding	43.86	35.65	28.86	18.46	1.01